Delfi Diagnostics is a cutting-edge startup that operates in the healthcare sector, specifically in the field of cancer detection. The company leverages advanced machine learning and a new field called fragmentomics to analyze fragments of cell-free DNA for early cancer detection. Unlike traditional screening methods that focus on known cancer-associated mutations, Delfi's technology scans millions of data points to identify previously unrecognized cancer-associated fragments. This innovative approach allows for a more comprehensive and potentially earlier detection of cancer.

The company's team is composed of leading experts in cancer biology, bioinformatics, machine learning, and public health. The CEO and founder, Dr. Victor Velculescu, is internationally recognized for his contributions to genomics and cancer research. The team's combined expertise and experience in various fields, including next-generation sequencing, bioinformatics, and regulated software development, position Delfi Diagnostics as a leader in the healthcare technology market.

Delfi Diagnostics' business model revolves around the development and commercialization of their novel healthcare technologies. The company generates revenue by offering their advanced cancer detection services to healthcare providers and patients. Their innovative approach to cancer screening has the potential to revolutionize the healthcare industry by providing a more efficient and effective method for early cancer detection.

Keywords: Delfi Diagnostics, Healthcare Technology, Cancer Detection, Machine Learning, Fragmentomics, Cell-free DNA, Genomics, Bioinformatics, Next-Generation Sequencing, Early Cancer Detection.